{"nctId":"NCT01565707","briefTitle":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","startDateStruct":{"date":"2012-06-07","type":"ACTUAL"},"conditions":["Urinary Bladder, Overactive"],"count":189,"armGroups":[{"label":"Placebo Children","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Urotherapy"]},{"label":"Solifenacin Succinate Suspension Children","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin Succinate Suspension","Behavioral: Urotherapy"]},{"label":"Placebo Adolescents","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Urotherapy"]},{"label":"Solifenacin Succinate Suspension Adolescents","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Solifenacin Succinate Suspension","Behavioral: Urotherapy"]}],"interventions":[{"name":"Solifenacin Succinate Suspension","otherNames":["YM905"]},{"name":"Placebo","otherNames":[]},{"name":"Urotherapy","otherNames":["Bladder training"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Written Informed Consent has been obtained\n* OAB (symptoms of urgency) according to International Children's Continence Society (ICCS) criteria\n* Daytime incontinence with at least 4 or more episodes of incontinence confirmed by 7 day participant diary\n\nMain Exclusion Criteria:\n\n* Daily voiding frequency less than 5\n* Extraordinary daytime urinary frequency according to the International Children's Continence Society (ICCS) definition\n* Uroflow indicative of pathology other than OAB\n* Maximum voided volume (morning volume excluded) \\> expected bladder capacity for age \\[(age +1) x 30\\] in ml or a maximum voided volume (morning volume excluded) above 390 ml\n* Post Void Residual (PVR) \\> 20 ml\n* Monosymptomatic enuresis\n* Polyuria defined as \\> 75 ml/kg/b.w./24 hours\n* Dysfunctional voiding\n* Congenital anomalies affecting lower urinary tract function\n* Current constipation\n* Current Urinary Tract Infection (UTI)\n* Catheterization within 2 weeks prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition","description":"The mean voided volume was calculated from the participant diary data recorded during two measuring days (i.e., those days when the participant recorded the volume of each micturition) in the 7 days prior to the baseline and end of treatment visits. The MVV is equal to the mean of the non-zero volumes recorded over the 2 measuring days. A micturition is any voluntary urination, excluding episodes of incontinence.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"4.8"},{"groupId":"OG001","value":"25.5","spread":"4.8"},{"groupId":"OG002","value":"6.9","spread":"14.6"},{"groupId":"OG003","value":"2.3","spread":"14.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Daytime Maximum Volume Voided (DMaxVV) Per Micturition","description":"The mean daytime maximum volume voided (DMaxVV) was determined using the participant diary data recorded during two measuring days (i.e., those days when the participant recorded the volume of each micturition) in the 7 days prior to the Baseline and end of treatment visits. The daytime maximum volume voided (DMaxVV) is the largest (non-zero) volume recorded over both of the 2 measuring days in the diary. The first morning void is excluded from the calculation. Daytime is defined as the time between waking up in the morning and going to bed later the same day. A micturition is any voluntary urination, excluding episodes of incontinence.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"11.2"},{"groupId":"OG001","value":"43.2","spread":"11.1"},{"groupId":"OG002","value":"-8.4","spread":"27.0"},{"groupId":"OG003","value":"-25.7","spread":"26.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours","description":"An incontinence episode is defined as an episode with any involuntary loss of urine. The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.2"},{"groupId":"OG001","value":"-1.1","spread":"0.2"},{"groupId":"OG002","value":"-0.7","spread":"0.4"},{"groupId":"OG003","value":"-0.6","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Daytime Incontinence Episodes Per 24 Hours","description":"The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. An incontinence episode is defined as an episode with any involuntary loss of urine. Daytime is defined as the time between waking up in the morning and going to bed later the same day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.2"},{"groupId":"OG001","value":"-1.2","spread":"0.2"},{"groupId":"OG002","value":"-0.2","spread":"0.4"},{"groupId":"OG003","value":"-0.8","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Nighttime Incontinence Episodes Per 24 Hours","description":"The mean number of incontinence episodes was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. An incontinence episode is defined as an episode with any involuntary loss of urine. Nighttime is defined as the time between going to bed and waking up the following morning.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.0"},{"groupId":"OG001","value":"-0.1","spread":"0.0"},{"groupId":"OG002","value":"-0.2","spread":"0.1"},{"groupId":"OG003","value":"-0.2","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Dry (Incontinence-Free) Days Per 7 Days","description":"The mean number of dry days was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. An incontinence episode is defined as an episode with any involuntary loss of urine.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.3"},{"groupId":"OG001","value":"1.3","spread":"0.3"},{"groupId":"OG002","value":"1.5","spread":"0.8"},{"groupId":"OG003","value":"1.6","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Dry (Incontinence-Free) Nighttimes Per 7 Days","description":"The mean number of dry nights was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. An incontinence episode is defined as an episode with any involuntary loss of urine.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.2"},{"groupId":"OG001","value":"0.4","spread":"0.2"},{"groupId":"OG002","value":"-0.1","spread":"0.4"},{"groupId":"OG003","value":"0.4","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours","description":"The mean number of micturitions was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. A micturition is any voluntary urination, excluding episodes of incontinence.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.2"},{"groupId":"OG001","value":"-1.1","spread":"0.2"},{"groupId":"OG002","value":"-0.6","spread":"0.5"},{"groupId":"OG003","value":"-0.4","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Daytime Micturitions Per 24 Hours","description":"The mean number of micturitions was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. A micturition is any voluntary urination, excluding episodes of incontinence. Daytime is defined as the time between waking up in the morning and going to bed later the same day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.2"},{"groupId":"OG001","value":"-1.2","spread":"0.2"},{"groupId":"OG002","value":"-0.5","spread":"0.5"},{"groupId":"OG003","value":"-0.3","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Nighttime Micturitions Per 24 Hours","description":"The mean number of micturitions was determined using the patient diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit. A micturition is any voluntary urination, excluding episodes of incontinence. Nighttime is defined as the time between going to bed and waking up the following morning.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.1"},{"groupId":"OG001","value":"-0.1","spread":"0.1"},{"groupId":"OG002","value":"0.4","spread":"0.3"},{"groupId":"OG003","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Mean Number of Grade 3 or 4 Urgency Episodes Per 24 Hours in Adolescents","description":"Adolescent participants were asked to record the degree of urgency associated with each micturition and incontinence episode according to the Patient Perception of Intensity of Urgency Scale (PPIUS) scale (0 - no urgency, 1 - mild urgency, 2 - moderate urgency, 3 - severe urgency, 4 - urge incontinence). The mean number of grade 3 or 4 urgency episodes was determined using using diary data recorded by the participant in the 7 days prior to baseline visit and end of treatment visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.5"},{"groupId":"OG001","value":"-1.0","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment. Cmax could not be calculated for 2 children and 1 adolescent in the Pharmacokinetic Analysis Set (PKAS).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"4.593"},{"groupId":"OG001","value":"26.24","spread":"6.617"},{"groupId":"OG002","value":"17.08","spread":"NA"},{"groupId":"OG003","value":"33.48","spread":"11.93"},{"groupId":"OG004","value":"42.85","spread":"21.44"}]}]}]},{"type":"SECONDARY","title":"Time to Attain Maximum Concentration (Tmax) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment. Tmax could not be calculated for 2 children and 1 adolescent in the PKAS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.933","spread":"0.5354"},{"groupId":"OG001","value":"3.175","spread":"0.561"},{"groupId":"OG002","value":"2.8","spread":"NA"},{"groupId":"OG003","value":"2.874","spread":"0.5268"},{"groupId":"OG004","value":"2.85","spread":"0.4733"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration Before Drug Administration (Ctrough) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment. Ctrough could not be calculated for 2 children and 1 adolescent in the PKAS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.534","spread":"3.083"},{"groupId":"OG001","value":"16.1","spread":"4.951"},{"groupId":"OG002","value":"8.828","spread":"NA"},{"groupId":"OG003","value":"19.05","spread":"8.7"},{"groupId":"OG004","value":"27.94","spread":"16.76"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration - Time to Curve (AUC) for a Dose Interval (AUCtau) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"298.7","spread":"80.35"},{"groupId":"OG001","value":"452.8","spread":"112.6"},{"groupId":"OG002","value":"269.2","spread":"NA"},{"groupId":"OG003","value":"560","spread":"216.8"},{"groupId":"OG004","value":"745.7","spread":"411"}]}]}]},{"type":"SECONDARY","title":"Apparent Terminal Elimination Half-Life (T1/2) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":"5.486"},{"groupId":"OG001","value":"30.98","spread":"7.147"},{"groupId":"OG002","value":"24.84","spread":"NA"},{"groupId":"OG003","value":"26.85","spread":"7.475"},{"groupId":"OG004","value":"41.27","spread":"17.44"}]}]}]},{"type":"SECONDARY","title":"Apparent Total Body Clearance (CL/F) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.968","spread":"2.129"},{"groupId":"OG001","value":"7.608","spread":"1.782"},{"groupId":"OG002","value":"14.56","spread":"NA"},{"groupId":"OG003","value":"8.773","spread":"3.763"},{"groupId":"OG004","value":"11.3","spread":"7.294"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vz/F) of Solifenacin","description":"Pharmacokinetic sampling was performed at steady state at the end of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"272.4","spread":"96.84"},{"groupId":"OG001","value":"329.5","spread":"63.32"},{"groupId":"OG002","value":"521.9","spread":"NA"},{"groupId":"OG003","value":"315.7","spread":"96.23"},{"groupId":"OG004","value":"561.7","spread":"181.7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"A treatment emergent adverse event (TEAE) was defined as an AE that occurred after the first dose of study drug and within 7 days after last dose of study medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Post Void Residual (PVR) Volume","description":"Post Void Residual (PVR) Volume was assessed by ultrasonography or bladder scan.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"7.28"},{"groupId":"OG001","value":"-0.99","spread":"6.45"},{"groupId":"OG002","value":"-3.58","spread":"4.72"},{"groupId":"OG003","value":"0.95","spread":"9.85"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":73},"commonTop":["Nasopharyngitis","Diarrhoea","Electrocardiogram QT prolonged","Headache","Escherichia urinary tract infection"]}}}